Company intelligence / Profile preview

HLH Biopharma

Ownership: Private
Development stage: Other

Overview

HLH Biopharma is a biotechnology company dedicated to developing targeted therapies for Hemophagocytic Lymphohistiocytosis (HLH) and related hyperinflammatory conditions. The company's primary focus is on the development of HLH-101, a selective Janus kinase 1 (JAK1) inhibitor designed to manage the life-threatening cytokine storms associated with primary and secondary HLH. By targeting the JAK/STAT signaling pathway, HLH Biopharma aims to provide more precise and less toxic treatment options compared to current standard-of-care chemotherapy and immunosuppression. The company is currently advancing its lead candidate through pre-clinical studies to support future clinical applications in pediatric and adult populations.

Therapeutic areas: HematologyImmunologyRheumatology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on HLH Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLH Biopharma.

Explore the full profile